Clinical trials: Allergy in Children
Food Allergy
Open-label Extension Study of ADP101
This is an open-label, safety extension study for participants who participated in the Harmony study (protocol ADP101-MA-01).
- Trial name
- NCT05243719
- Testing
- ADP101
- Where
- 14 sites in United States
- Volunteers
- 45 people
- Sponsor
- Alladapt Immunotherapeutics, Inc.
Peanut Allergy
PALISADE Follow-on Study (ARC004)
The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through oral immunotherapy (OIT) in peanut-allergic children and adults who have completed the ARC003 study.
- Trial name
- NCT02993107
- Testing
- AR101
- Where
- 65 sites in United States, Canada and 7 more
- Volunteers
- 388 people
- Sponsor
- Aimmune Therapeutics, Inc.
Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
This trial will assess the safety, efficacy and tolerability of ACZ885 in patients aged 4 years and younger with cryopyrin associated periodic syndromes (CAPS)
- Conditions
- Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
- Trial name
- NCT01302860
- Testing
- ACZ885
- Where
- 12 sites in Belgium, Canada and 5 more
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals
Dermatitis, Atopic
An Observational Study to Gather Real-World User Feedback on DIPROBASE® Advanced Eczema Cream in Adults and Children With Eczema or Dry Skin
This is an observational study which means only data are collected from participants about their experience and symptoms, who received their usual treatment without any intervention from the study sponsor.
- Trial name
- NCT06747897
- Testing
- MINERAL OIL + PETROLATUM (DIPROBASE® Advanced Eczema Cream, BAY987534, UI 1613882)
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Bayer
Asthma
To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.
To compare the pharmacokinetics of budesonide delivered by BDA MDI to budesonide delivered by Pulmicort Respules in children with Asthma aged 4 to 8 years.
- Trial name
- BLANC (NCT04848662)
- Testing
- BDA MDI (PT027) 160/180 μg, Pulmicort Respules 0.5 MG/ML Inhalation Suspension
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Bond Avillion 2 Development LP
Rhinitis, Allergic, Perennial
Cetirizine Placebo Controlled Study For Perennial Allergic Rhinitis
Study objective is to verify the superiority of CTZ DS to the placebo groups in the change of total nasal symptom score (TNSS) over the total treatment period from the score of the baseline assessment period.
- Trial name
- NCT00490204
- Testing
- Cetirizine
- Where
- 28 sites in Japan
- Volunteers
- 239 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis
This is a multicenter, double-blind, vehicle-control study of 0.05% and 0.2% E6005 ointment. Pediatric subjects with atopic dermatitis (AD) will be grouped into two; an elder group (childhood - adolescent: 7 to 15 years of age)…
- Trial name
- NCT02094235
- Testing
- E6005 0.05%, E6005 0.2%
- Where
- 3 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Organon and Co
Asthma
A Study to Determine the Effect of Montelukast Sodium as an Episode Modifier in the Treatment of Infrequent Episodic Asthma in Children (0476-165)
A 53-week study to determine the effect of montelukast sodium when given to children (with infrequent episodic asthma) at the earliest symptoms of an acute episode of asthma.
- Trial name
- NCT00140881
- Testing
- MK0476; montelukast sodium
- Volunteers
- 220 people
- Sponsor
- Organon and Co
Dermatitis, Atopic
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
The purpose of this study is to investigate the safety and efficacy of AN2728 Topical Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis.
- Trial name
- NCT02118766
- Testing
- AN2728 Topical Ointment, 2%, Matching vehicle control
- Where
- United States
- Volunteers
- 763 people
- Sponsor
- Pfizer
Asthma
Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma
This study will evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged ≥ 5 to 11 years with asthma.
- Trial name
- TRAILHEAD (NCT04673630)
- Testing
- Tezepelumab
- Where
- 6 sites in Hungary, South Africa and 1 more
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Dermatitis, Atopic
A Study of a Moisturizing Cream and Baby Wash in the Management of Mild to Moderate Atopic Dermatitis in Infants, Toddlers and Children
The purpose of this study is to evaluate the effectiveness (assessed by clinical evaluation of eczema/atopic dermatitis severity and parent-perceived benefits) and tolerability (assessed by clinical grading and parent-perception)…
- Trial name
- NCT04740892
- Testing
- Wash IP, Cream IP
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Asthma
Measurement of FeNO in Young Children With the NIOX VERO
FeNO measurements provide the physician with means of evaluating an asthma patient's response to anti-inflammatory therapy, as an adjunct to the established clinical and laboratory assessments in asthma.
- Trial name
- NCT02661984
- Where
- 3 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Aerocrine AB
Asthma
Asthma in Children
This is a six-month non-interventional prospective study of various controller therapies in children with asthma in outpatient clinical practice.
- Trial name
- NCT01286532
- Where
- 11 sites in Russia
- Volunteers
- 283 people
- Sponsor
- AstraZeneca
Allergic Conjunctivitis
Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children
This is a multi-centre, randomised, double blind, placebo-controlled, parallel-group, phase III study to assess the safety, tolerability and efficacy of Bilastine ophthalmic solution 0.6% in children with a documented history of…
- Trial name
- NCT04810390
- Testing
- Bilastine
- Where
- 18 sites in Spain
- Volunteers
- 59 people
- Sponsor
- Faes Farma, S.A.
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to <18 Years Old) with moderate atopic dermatitis.
- Trial name
- TRuE-AD5 (NCT06832618)
- Testing
- Ruxolitinib, Vehicle Cream
- Where
- 93 sites in United States, Belgium and 8 more
- Volunteers
- 159 people
- Sponsor
- Incyte Corporation
Asthma
Open-label, Safety and Efficacy Study of Pulmicort® Turbuhaler® in Japanese Children With Bronchial Asthma
To investigate the effect and safety of budesonide Turbuhaler® 100 μg/dose and 200 μg/dose twice daily for 6 weeks in Japanese children with bronchial asthma aged 5 years to 15 years old in need for inhaled glucocorticosteroid…
- Trial name
- NCT00504062
- Testing
- budesonide, fluticasone
- Where
- Japan
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Asthma
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
This purpose of the study is to investigate the bronchodilating effects of 3 different dosages of formoterol given in combination with budesonide as Symbicort pMDI.
- Trial name
- CHASE 2 (NCT01136655)
- Testing
- 80/2.25 μg Symbicort pMDI, 80/4.5 μg Symbicort pMDI, Foradil Aerolizer 12 μg
- Where
- 34 sites in United States, Bulgaria and 4 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Asthma
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
The purpose of this study is to evaluate the superiority in terms of efficacy and evaluate the safety of QMF149 (indacaterol (acetate) / mometasone (furoate)) compared to budesonide in children from 6 to less than 12 years of age…
- Trial name
- NCT05562466
- Testing
- QMF149, Budesonide
- Where
- 65 sites in Argentina, Austria and 15 more
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)
The primary objective of this study is to demonstrate the dose-related efficacy, by evaluating morning (AM) lung function at the end of the dosing interval (AM pre-dose percent predicted forced expiratory volume in one second…
- Trial name
- NCT01502371
- Testing
- Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg, Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg, Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg
- Volunteers
- 583 people
- Sponsor
- Organon and Co
Asthma
GSK2190915 Pediatric Study
GSK2190915 is under development as an oral controller for the treatment of adult and pediatric asthma. This study is an open label, single and repeat dose escalation study, in children with asthma.
- Trial name
- NCT01286844
- Testing
- GSK2190915A 5mg, GSK2190915A 10mg, GSK2190915A 25mg
- Sponsor
- GlaxoSmithKline